| Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction SD Solomon, JJV McMurray, B Claggett, RA de Boer, D DeMets, ... New England Journal of Medicine 387 (12), 1089-1098, 2022 | 1241 | 2022 |
| Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial MN Kosiborod, PS Jhund, KF Docherty, M Diez, MC Petrie, S Verma, ... Circulation 141 (2), 90-99, 2020 | 343 | 2020 |
| Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial SD Solomon, RA de Boer, D DeMets, AF Hernandez, SE Inzucchi, ... European journal of heart failure 23 (7), 1217-1225, 2021 | 293 | 2021 |
| Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial D Lindholm, C Varenhorst, CP Cannon, RA Harrington, A Himmelmann, ... European heart journal 35 (31), 2083-2093, 2014 | 286 | 2014 |
| Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER PS Jhund, T Kondo, JH Butt, KF Docherty, BL Claggett, AS Desai, ... Nature medicine 28 (9), 1956-1964, 2022 | 191 | 2022 |
| Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF AM Jackson, P Dewan, IS Anand, J Bělohlávek, O Bengtsson, RA de Boer, ... Circulation 142 (11), 1040-1054, 2020 | 159 | 2020 |
| Clinical and genetic determinants of varicose veins: prospective, community-based study of≈ 500 000 individuals E Fukaya, AM Flores, D Lindholm, S Gustafsson, D Zanetti, E Ingelsson, ... Circulation 138 (25), 2869-2880, 2018 | 145 | 2018 |
| Effect of dapagliflozin in patients with HFrEF treated with sacubitril/valsartan: the DAPA-HF trial SD Solomon, PS Jhund, BL Claggett, P Dewan, L Køber, MN Kosiborod, ... Heart Failure 8 (10), 811-818, 2020 | 133 | 2020 |
| Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in Non–ST-Elevation acute coronary syndrome patients managed with or without in-hospital … L Wallentin, D Lindholm, A Siegbahn, L Wernroth, RC Becker, ... Circulation 129 (3), 293-303, 2014 | 131 | 2014 |
| Biomarker-based risk model to predict cardiovascular mortality in patients with stable coronary disease D Lindholm, J Lindbäck, PW Armstrong, A Budaj, CP Cannon, ... Journal of the American College of Cardiology 70 (7), 813-826, 2017 | 124 | 2017 |
| Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial SD Solomon, M Vaduganathan, BL Claggett, RA de Boer, D DeMets, ... Heart Failure 10 (3), 184-197, 2022 | 109 | 2022 |
| Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF L Shen, SL Kristensen, O Bengtsson, M Böhm, RA de Boer, KF Docherty, ... Heart Failure 9 (4), 254-264, 2021 | 104 | 2021 |
| Effect of temozolomide in patients with metastatic bronchial carcinoids J Crona, I Fanola, DP Lindholm, P Antonodimitrakis, K Öberg, B Eriksson, ... Neuroendocrinology 98 (2), 151-155, 2013 | 101 | 2013 |
| Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF trial JH Butt, P Dewan, B Merkely, J Belohlávek, J Drożdż, M Kitakaze, ... Annals of Internal Medicine 175 (6), 820-830, 2022 | 78 | 2022 |
| Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial JH Butt, PS Jhund, J Belohlávek, RA de Boer, CE Chiang, AS Desai, ... Circulation 146 (16), 1210-1224, 2022 | 74 | 2022 |
| Association of multiple biomarkers with risk of all-cause and cause-specific mortality after acute coronary syndromes: a secondary analysis of the PLATO biomarker study D Lindholm, SK James, K Gabrysch, RF Storey, A Himmelmann, ... JAMA cardiology 3 (12), 1160-1166, 2018 | 72 | 2018 |
| Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF KF Docherty, PS Jhund, I Anand, O Bengtsson, M Böhm, RA de Boer, ... Circulation 142 (17), 1623-1632, 2020 | 68 | 2020 |
| Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction JW Cunningham, M Vaduganathan, BL Claggett, IJ Kulac, AS Desai, ... Journal of the American College of Cardiology 80 (14), 1302-1310, 2022 | 65 | 2022 |
| Early diagnosis of acute coronary syndrome H Katus, A Ziegler, O Ekinci, E Giannitsis, WG Stough, S Achenbach, ... European heart journal 38 (41), 3049-3055, 2017 | 65 | 2017 |
| Iron deficiency in heart failure and effect of dapagliflozin: findings from DAPA-HF KF Docherty, P Welsh, S Verma, RA De Boer, E O’Meara, O Bengtsson, ... Circulation 146 (13), 980-994, 2022 | 64 | 2022 |
John McMurrayUniversity of Glasgow.Verified email at glasgow.ac.uk
